AbbVie recently announced its publication in The Lancet showing that administration of Ubrelvy (ubrogepant) during the prodrome stage of a migraine can reduce the likelihood of a migraine attack developing. Ubrelvy is the first and only acute migraine treatment that has demonstrated Phase III data in the prodrome stage.
Christie Wong, Pharma Analyst at GlobalData, comments: “The prodrome stage of a migraine occurs between one to six hours before the onset of a migraine attack, and the symptoms can include sensitivity to light and sound, fatigue, and neck stiffness and/or pain. However, not all migraine patients experience prodromal symptoms, and the migraine stages may vary in terms of duration and severity between patients. Thus, Ubrelvy could provide an additional benefit to a subset of migraine patients who are able to identify prodromal symptoms.”
There are many acute treatments for migraine pain relief, but some patients cannot tolerate triptans, which are the gold standard treatment. Ubrelvy could give patients who are able to identify prodromal symptoms the ability to treat migraine during the early stages.
Ubrelvy is the first and only acute migraine treatment that has demonstrated Phase III data in the prodrome stage.
Read headache articles in ACNR’s Headache Archives
